117 related articles for article (PubMed ID: 22348216)
1. [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
Cumová J; Jedličková L; Potěšil D; Sedo O; Stejskal K; Potáčová A; Zdráhal Z; Hájek R
Klin Onkol; 2012; 25(1):17-25. PubMed ID: 22348216
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Hsieh FY; Tengstrand E; Pekol TM; Guerciolini R; Miwa G
J Pharm Biomed Anal; 2009 Jan; 49(1):115-22. PubMed ID: 19062221
[TBL] [Abstract][Full Text] [Related]
3. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
6. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
9. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map.
Cho SY; Lee EY; Lee JS; Kim HY; Park JM; Kwon MS; Park YK; Lee HJ; Kang MJ; Kim JY; Yoo JS; Park SJ; Cho JW; Kim HS; Paik YK
Proteomics; 2005 Aug; 5(13):3386-96. PubMed ID: 16047310
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Manochakian R; Miller KC; Chanan-Khan AA
Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
[TBL] [Abstract][Full Text] [Related]
12. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
[TBL] [Abstract][Full Text] [Related]
13. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
14. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
[TBL] [Abstract][Full Text] [Related]
15. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib and its role in the management of patients with multiple myeloma.
Orlowski RZ
Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
20. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
